Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Phase 2 trial evaluates entospletinib in DLBCL

Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Publish date:: October 12, 2018

Key clinical point: Entospletinib has limited activity against relapsed/refractory diffuse large B-cell lymphoma and a high rate of adverse events.

Major finding: The rate of progression-free survival at 16 weeks was 3.6% with a median PFS of 1.5 months.

Study details: An analysis of 43 relapsed/refractory DLBCL patients who received single-agent entospletinib.

Disclosures: The study was supported by Gilead Sciences. Dr. Burke reported relationships with Gilead and other companies.

Read the article here.

Citation:

Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,